Hyperglycaemia increases the risk of developing diabetic nephropathy, with primary targets in the glomerulus and proximal tubule. Importantly, glomerular damage in the kidney leads to elevated albumin levels in the filtrate, which contributes to tubular structural modifications that leads to dysfunction. Diabetes alters the endocannabinoid system in a number of target organs, with previous research characterising tissue-specific changes in the expression of the cannabinoid receptor 1 (CB1 ) and putative cannabinoid receptor, GPR55, in diabetes. Despite a functional role for the cannabinoid system in the kidney, there has been little investigation into changes in the expression of CB1 and GPR55 in the proximal tubule under diabetic conditions. CB1 and GPR55 mRNA and protein levels were quantified in cultured human kidney (HK2) cells, treated with either elevated glucose or albumin in isolation and in combination, for a period of 4, 6, 18 or 24 hours. In addition, CB1 and GPR55 protein expression was characterized in whole kidney lysate from streptozotocin (STZ) induced diabetic Sprague Dawley rats. In vitro, exposure to elevated glucose and albumin increased both CB1 and GPR55 mRNA and protein expression in proximal tubule cells in a time-dependant manner. In whole kidney of STZ-induced diabetic rats, CB1 protein was upregulated, whereas GPR55 protein concentration was not altered. Thus, expression of CB1 and GPR55 in proximal tubules is altered in response to exposure to elevated levels of glucose and albumin. Further investigations should determine if these receptors are effective physiological targets for the treatment and prevention of diabetic nephropathy. This article is protected by copyright. All rights reserved.
Pharmacology, Toxicology and Pharmaceutical Science
5
14%
Biochemistry, Genetics and Molecular Biology
5
14%
Agricultural and Biological Sciences
5
14%
Chemistry
3
8%
Other
2
6%
Unknown
9
25%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2015.
All research outputs
#23,938,347
of 34,360,257 outputs
Outputs from Clinical & Experimental Pharmacology & Physiology
#1,225
of 1,816 outputs
Outputs of similar age
#276,690
of 416,088 outputs
Outputs of similar age from Clinical & Experimental Pharmacology & Physiology
#9
of 17 outputs
Altmetric has tracked 34,360,257 research outputs across all sources so far. This one is in the 29th percentile – i.e., 29% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,816 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,088 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
